4basebio Plc - 4basebio anuncia el suministro de sus productos de ADN opDNA™ al programa de vacunas del cliente farmacéutico de nivel 1
4basebio Plc - 4basebio anuncia el suministro de sus productos de ADN opDNA™ al programa de vacunas del cliente farmacéutico de nivel 1
PR Newswire
LONDRES, Reino Unido, 10 de abril
10 de abril de 2024
PLC 4basebio
("4basebio" o la "Compañía")
4basebio announces the supply of its opDNA™ DNA products into Tier 1 Pharma client’s vaccine program
Cambridge, Reino Unido, 10 de abril de 2024 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform, today announces the supply of its HQ synthetic DNA to a Tier 1 Pharma Company. Following successful completion of an opDNA™ evaluation study, our client has now progressed to HQ opDNA™ for late preclinical studies for an mRNA vaccine program. Supply of GMP grade material for clinical trials is anticipated in Q3.
Este anuncio contiene información privilegiada a los efectos del artículo 7 del Reglamento de la UE 596/2014, modificado por el reglamento 11 del reglamento de abuso de mercado (enmienda) (Salida de la UE) 2019/310.
Dr Heikki Lanckriet, CEO at the Company, commented: "This is a major achievement for our company and is significant both in terms of product quantity and value. It’s a clear recognition of the strengths of our synthetic DNA products, our product quality, and our manufacturing capabilities.
“There is strong interest in our synthetic DNA products, and we are now supporting a growing number of projects into the clinic. We expect client acquisition and revenue generation to continue accelerating as our expanding client base progress their clinical programs.”
Para más consultas, contáctese con:
PLC 4basebio Heikki Lanckriet | 44 0 12 2396 7943 |
Asesor Nominado Asesores financieros de Cairn LLP Jo Tuner/Sandy Jamieson | 44 0 20 7213 0880 |
Broker Cavendish Capital Markets Limitado Geoff Nash / Charlie Beeson / Nigel Birks | 44 0 20 7220 0500 |
Comunicaciones de Lionsgate (consultas de los medios) jonathan charles | 44 0 77 |
Notas a los editores
Acerca de 4basebio
4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients. The company is offering GMP compliant DNA starting materials suitable for use in AAV viral vector production as well as mRNA vaccine and therapeutics production.
Declaraciones prospectivas
Este anuncio puede contener ciertas declaraciones sobre las perspectivas futuras de 4basebio. Aunque los directores creen que sus expectativas se basan en suposiciones razonables, cualquier declaración sobre perspectivas futuras puede verse influenciada por factores que podrían causar que los resultados reales sean materialmente diferentes.